TRVI stock forecast, quote, news & analysis
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC... Show more
Trevi Therapeutics (TRVI) Stock Analysis: Haduvio Clinical Progress Meets Favorable Competitive Landscape
Key Takeaways
- Trevi Therapeutics shares traded near $18.09 as of late July 2026, with modest fluctuations over the past 30 days as the stock consolidated gains from a strong multi-month rally.
- GSK's decision to discontinue its competing P2X3 antagonist camlipixant in refractory chronic cough removed a major competitor, leaving Haduvio as the leading differentiated candidate in the space.
- The company's pro forma cash position of approximately $334 million, following a $162 million April 2026 stock offering, extends its runway into 2030 and funds multiple pivotal clinical trials.
- Analyst sentiment remains overwhelmingly bullish, with 11 analysts maintaining a consensus "Strong Buy" rating and an average price target of $26.18, implying over 44% upside from current levels.
- Upcoming catalysts include the initiation of two Phase 3 IPF-related chronic cough trials, a Phase 2b refractory chronic cough trial, and a sample size re-estimation readout expected in the fourth quarter of 2026.
Current Market Snapshot
Trevi Therapeutics (TRVI) has been trading in a relatively tight range over the past 30 days, with the stock consolidating near the $18 level after a powerful rally earlier in 2026. Shares have pulled back modestly from a 52-week high of $20.22 reached in early July, reflecting some profit-taking following the sharp run-up driven by positive clinical data and competitive developments. The 50-day moving average sits near $15.85, while the 200-day moving average hovers around $13.40, underscoring the stock's significant appreciation year-to-date. With a market capitalization of approximately $2.6 billion and institutional ownership exceeding 95%, TRVI has attracted substantial attention from both healthcare-focused and generalist investors drawn to the Haduvio development story.
Trevi Therapeutics (TRVI) Business Overview and Competitive Position
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine extended-release) for chronic cough indications with high unmet medical need. The company's lead programs target chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC) — conditions that collectively affect millions of patients and currently have no FDA-approved therapies. Haduvio's dual mechanism of action as a kappa agonist and mu antagonist (KAMA) targets opioid receptors central to the cough reflex arc. The drug has demonstrated statistically significant reductions in cough frequency across both IPF and RCC patient populations in Phase 2 trials, positioning it as a potential first-in-class treatment. Trevi owns worldwide rights to Haduvio and has secured method-of-treatment patents extending through 2039, with additional applications that could extend coverage to 2046.
Recent Developments Driving TRVI
The most consequential recent development for Trevi Therapeutics came in mid-July 2026 when GSK announced it was halting development of camlipixant, its P2X3 receptor antagonist for refractory chronic cough, after mixed Phase 3 results. The news triggered a sharp rally in TRVI shares, as Haduvio became the clear leading candidate in the chronic cough space. B. Riley responded by raising its price target to $31 from $21, while HC Wainwright lifted its target to $24 and BMO Capital initiated coverage with a Buy rating and a $36 target. On the clinical front, Trevi reported positive topline results from its Phase 2b CORAL trial demonstrating dose-dependent cough reduction of up to 60.2% with Haduvio, and completed an End-of-Phase 2 meeting with the FDA that provided overall alignment on the Phase 3 development path. The company also successfully raised $162 million in an April stock offering, extending its cash runway into 2030. Offsetting these positives, TRVI was removed from several Russell indices in late June 2026 and reported a Q1 2026 EPS loss of $0.09, missing consensus estimates by $0.02.
Trending AI Robots
For investors seeking data-driven insights beyond traditional stock analysis, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron hosts hundreds of AI-driven trading bots that actively trade thousands of tickers across various strategies, timeframes, and performance profiles. The Trending AI Robots section highlights only the most relevant and consistently performing bots, making it easier for users to identify AI trading strategies that align with their investment approach. Each bot varies in its methodology — from short-term momentum plays to longer-term value-oriented strategies — and users can review key performance metrics directly on the platform. Exploring this section can help traders and investors discover AI-driven tools to complement their own market research.
2026 Outlook and What Investors Should Watch
The remainder of 2026 is poised to be a pivotal execution period for Trevi Therapeutics. Investors should monitor the initiation and enrollment progress of the two parallel Phase 3 trials for IPF-related chronic cough, with the first trial expected to begin in the second quarter and the second in the second half of 2026. Topline data from these studies is anticipated in the first half of 2028 and second half of 2027, respectively. Near-term catalysts include the initiation of the Phase 2b refractory chronic cough trial and its sample size re-estimation readout in Q4 2026, which could provide early signals of Haduvio's efficacy in the broader RCC population. The company also plans to initiate an adaptive Phase 2b/3 trial for non-IPF ILD-related chronic cough in the second half of 2026, pending FDA protocol review. On the financial side, while Trevi's cash runway through 2030 provides ample funding for the current development plan, investors should be aware that the company remains pre-revenue and cash-burn rates may increase as multiple late-stage trials progress simultaneously. Additional analyst coverage, institutional positioning following the Russell index removal, and potential partnership or licensing discussions represent other factors that could influence the stock's trajectory through year-end.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TRVI in upward trend: price may jump up because it broke its lower Bollinger Band on July 13, 2026
TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where TRVI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 74 cases where TRVI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 174 cases where TRVI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for TRVI moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRVI as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TRVI turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.060) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of neurological products
Industry Biotechnology